Personalized drug plans may lower uncontrolled blood pressure risk in hypertension patients

This trial involved 776 outpatients with high blood pressure at eight hospitals. Participants received either personalized medication regimens adjusted for seven specific genetic markers or standard treatment approaches. The study followed patients for eight weeks total, split into two four-week periods. Researchers found that the personalized group had a notably higher rate of blood pressure control compared to the standard group. Additionally, patients in the personalized group required fewer antihypertensive medications overall. The risk of uncontrolled blood pressure was significantly lowered by the personalized approach. Safety data showed no significant difference in adverse events between the two groups. Reactions to common drug classes like beta-blockers and calcium channel blockers were monitored but did not differ significantly. The study highlights the potential of using genetic information to guide therapy in hypertension management. Readers should note this was a specific trial and results may vary for individuals. This evidence suggests a promising direction for precision medicine but does not replace standard care advice.